Cambridge, UK: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Dr. Lindsey Foulkes as the Company’s Chief Operating Officer.

Lindsey brings a wealth of deep expertise and experience from the life science industry, with roles covering strategy, marketing, project management and corporate development. Having completed a PhD in Immunology, she started her commercial career in consultancy with McKinsey & Company in 1995 before moving to help establish Nexan Ltd, a medical device start-up. She has also worked in commercial roles at Acambis plc, a vaccine development company, and Cangene Corporation, an immune therapeutics company where she led Strategic Business Development from 2007-2011. Lindsey then worked as a freelance consultant, working with academic groups and companies across the biotech and pharmaceutical fields. In 2016 she joined Liminal Biosciences (previously known as Prometic), a Nasdaq listed multinational company focusing on rare diseases, where she was Senior Director of Business Development. At Liminal, she also managed major organisational changes, including steering the company’s late-stage clinical programmes. Lindsey joins the Executive team at Arecor.

Sarah Howell, Chief Executive Officer of Arecor, said:  "We’re thrilled that Lindsey is joining Arecor’s Executive team as we enter our next phase of growth.  Lindsey will play a key role in ensuring that we deliver on the key strategic goals that we set out at the time of our recent IPO. She brings extensive experience from across the innovative healthcare sector which will significantly strengthen our commercial and operational capabilities as we advance our internal proprietary pipeline and further expand our partnered portfolio.”

Lindsey Foulkes, of Arecor, said: “Arecor’s innovative Arestat™ technology has been validated through multiple partnerships with major pharmaceutical and biotechnology companies, as well as through the best-in-class clinical data achieved for its lead insulin programme AT247. I’m excited to be joining the Company as it scales up and look forward to working with the team to deliver the benefits of Arecor’s ability to enhance medicines to pharmaceutical partners and, ultimately, to patients.”

-ENDS-